The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IWWM-12 2024 | An ongoing clinical trial investigating sonrotoclax in Waldenström’s macroglobulinemia
Jeffrey Matous, MD, Colorado Blood Cancer Institute, Denver, CO, discusses the potential of sonrotoclax, a novel BCL2 inhibitor, in treating Waldenström’s macroglobulinemia (WM). Based on promising results from the BGB-11417-101 study (NCT04277637), where responses were observed across various dose levels, a larger Phase II trial (BGB-11417-203; NCT05952037) is now underway to further evaluate sonrotoclax in relapsed and treatment-naive patients. This interview took place at the 12th International Workshop on Waldenström’s Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So sonrotoclax is a novel BCL2 inhibitor, which in preclinical studies looks like it has enhanced activity relative to venetoclax and so it makes sense to study it in Waldenstrom’s and in other diseases where we use BCL2 inhibition. And so in our study it’s based on a study known as BGB-11417-101. This is a study looking at first-in-human dosing of sonrotoclax in patients who had a variety of different non-Hodgkin lymphomas including WM...
So sonrotoclax is a novel BCL2 inhibitor, which in preclinical studies looks like it has enhanced activity relative to venetoclax and so it makes sense to study it in Waldenstrom’s and in other diseases where we use BCL2 inhibition. And so in our study it’s based on a study known as BGB-11417-101. This is a study looking at first-in-human dosing of sonrotoclax in patients who had a variety of different non-Hodgkin lymphomas including WM. So in that whole group of patients, 20 patients had WM and those patients were studied at various dose levels. And across all dose levels responses were seen and the drug appeared to be well tolerated. And that provided the rationale for going on with a large Phase II trial which is our study, which is study 203. In this study, we’re going to have three cohorts treating patients who have relapsed and refractory WM, and an additional cohort treating treatment-naive patients with WM, examining the role of sonrotoclax in various degrees of relapsed and refractory disease. So we’re excited to do it. It’s just rolling out right now. I think it will accrue very well. We’ll have more data shortly, I hope.
Read more...
Disclosures
Consulting: BeiGene.
